知名基金经理官宣：“限购”！

Group 1 - The core viewpoint of the articles is that several funds managed by China Universal Asset Management have announced purchase limits to ensure stable operations and protect the interests of fund holders [1][2][9] - China Universal Medical Innovation Fund, managed by Guo Lan, will limit single account purchases to 100,000 yuan starting August 11 [3][4] - The China Universal Science and Technology Theme Fund, managed by Shao Jie, will also impose a limit on large purchases over 1 million yuan from August 11 [6][7] Group 2 - As of the end of Q2, the China Universal Medical Innovation Fund had a scale of 8.114 billion yuan, reflecting a nearly 20% increase year-on-year, with a one-year return of 80.12%, ranking in the top 2 of its category [4][5] - The fund manager, Guo Lan, maintains a positive outlook on the innovative drug sector, citing increasing global competitiveness of domestic companies and supportive domestic policies [5] - The China Universal Science and Technology Theme Fund has a one-year return of 84.33%, also ranking in the top 2 of its category, benefiting from the explosive growth in the technology sector [7][8] Group 3 - The recent trend of fund purchase limits is seen across the industry, with approximately 50 actively managed equity funds announcing similar restrictions since July [10][11] - The rationale behind these limits is to control fund size, maintain investment strategy effectiveness, and protect existing investors from potential losses due to market volatility [10][11] - Fund managers are increasingly focusing on stable growth and the long-term profitability of their products rather than short-term performance spikes [11]